Palatin Technologies Inc. (NYSE MKT:PTN) Q4 2020 Earnings Conference Call - Final Transcript

Sep 28, 2020 • 11:00 am ET

Previous

Palatin Technologies Inc. (NYSE MKT:PTN) Q4 2020 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Q & A
Executive
Carl Spana

for ultimate approval is that you hit one sign and one symptom in two Phase III registration studies.

So from us, as I said, there are multiple outcomes. As long as we hit one of the two co primaries, and show very strong evidence of effect on something on the opposite side, we will go forward and for say -- we'll go forward and progress in the Phase III. So that's the way I think about it.

With regards to some of the other things I would focus on are ocular comfort is important. Current therapies that are out there, Restasis, Xiidra, topical steroids, they generally all have tolerability issues, stinging off case, bumpiness types of things. So I think oculars health tolerability is a key commercial attribute and comfort is a key commercial attribute that we think PL-81 -- as PL-9643 is going to have.

Analyst
John Newman

Okay, great. Thank you.

Operator
Operator

Thank you very much. Our next question will come from Joe Pantginis, H.C. Wainwright.

Analyst
Joseph Pantginis

I hope everyone's well, and thanks for taking the question. Carl, I'm actually going to segue off of one of your wrapping up comments in your prepared script when you referenced Steve, and the commercial efforts ongoing right now for Vyleesi. So I wanted to see if there's any particular details you can share with us about, a, how you're really keeping the profile high. I know you touched on some things in your prepared comments. But more specifically, can you give any level with regard to how scripts are going and the type of coverage that current Vyleesi currently has? Thanks.

Executive
Carl Spana

I'm going to second pass that off to Steve, but I do want to just comment one thing that we didn't have in the prepared script. The process of distribution for Vyleesi was put in place by AMAG through two specialty pharmacies that Steve has relayed to you.

Unfortunately, due to the relatively rapid withdrawal of support for the product by AMAG in the fourth quarter of last year. That process of distribution. So now it's getting the product from the manufacturer to the pharmacy and from the pharmacy to the patient, needed some attention and so we say, tender loving care?

Before we would be in a position to really start evaluating the marketing of -- or the targeted marketing of Vyleesi. And we're now at the -- coming to the -- I mean, so although it's been very quiet from our perspective, and I know investors keep contacting and saying what's going on, we -- it's been a very, very busy period of time, particularly Steve and the commercial group, making sure that the patient access, so another -- we feel the product coming through the system and the patient experience is really optimized.

And he's done a great job with that. And now these pharmacies are really performing at a much higher level, really at a level that they need to be performing at. And we're now in a position to